Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test the hypothesis that growth hormone,
administered daily by subcutaneous injection for 2 years will result in a significantly
greater BMD Z-score over optimal standard therapy.
Phase:
Phase 3
Details
Lead Sponsor:
The Hospital for Sick Children
Treatments:
Calcium Calcium, Dietary Ergocalciferols Hormones Vitamin D Vitamins